Incorporated on 10th September 2013, TalkMed is the holding company of wholly-owned subsidiaries: Singapore Cancer Centre Pte. Ltd.; TalkMed Vietnam Pte. Ltd. (“TalkMed Vietnam”); and TalkMed China Pte. Ltd, as well as partially-owned subsidiaries: Stem Med Pte. Ltd. (“Stem Med”); TalkMed Chongqing Pte. Ltd.; Stem Med Indonesia Pte. Ltd.; DrSG Cellular Wellness Pte. Ltd.; CellVec Pte. Ltd. TalkMed also holds a 30% stake in Hong Kong Integrated Oncology Centre Holdings Limited (“HKH”). HKH is the controlling shareholder of Hong Kong Integrated Oncology Centre Limited (“HKIOC”) which operates an oncology centre that offers integrated cancer care across disciplines. Following the collaboration with Hong Kong Adventist Hospital, HKIOC now provides a comprehensive range of treatment (including surgery, radiotherapy and medication), diagnostic imaging and endoscopy services in Hong Kong.
The Company’s highly-trained doctors provide tertiary healthcare services to the oncology patients in the private sector in Singapore, through Parkway Cancer Centre (“PCC”). Tertiary healthcare involves specialised care of a high complexity requiring specialised skills, personnel and support services.
Our clinical functions involve attending to patients, examining and administering medical treatments and performing minor outpatient surgical procedures, prescribing medicines and conducting laboratory tests or diagnostic procedures. Other than reviewing the results of these investigations and follow-up patient care, we also coordinate the overall care-plan for cancer patients by liaising with other medical professionals including surgeons, radiation oncologists, radiologists, physicians and para-medical professionals.
Our medical oncology practice has an established track record of more than 15 years. Our palliative medical team works together with the rest of our doctors to provide an extra layer of support for cancer care so as to improve the quality of life for both the patient and the family. We believe that we have a team of reputable doctors and healthcare professionals who believe in maintaining the highest quality of medical excellence in administering oncology healthcare services and palliative care services to our patients. We intend to continue to attract such like-minded professionals to join us in our vision of providing quality medical oncology services and palliative care services and expand our healthcare network within Singapore and around the region where there is an increasing demand for such quality and personalized care.
Within the next two to three years, we also hope to expand our services to include the provision of surgical healthcare, development of cellular and target therapy for haematological as well as oncology patients.